Menu Search
Equities

Enlivex Therapeutics Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
1BT:STU

Enlivex Therapeutics Ltd

Actions
  • Price (EUR)0.965
  • Today's Change-0.01 / -1.03%
  • Shares traded0.00
  • 1 Year change-3.50%
  • Beta1.6376
Data delayed at least 15 minutes, as of Mar 03 2026.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Enlivex Ltd, formerly known as Enlivex Therapeutics Ltd, is an Israel-based clinical-stage macrophage reprogramming immunotherapy company developing Allocetra, an off-the-shelf cell therapy designed to restore macrophages to their homeostatic state. The Company focuses on diseases in which macrophages are pathologically reprogrammed, such as solid cancers, sepsis and COVID‑19, where non-homeostatic macrophages contribute significantly to disease severity. By re-establishing macrophage homeostasis, Allocetra has the potential to provide an immunotherapeutic mechanism of action for life-threatening indications defined as unmet medical needs, either as a stand‑alone therapy or in combination with other treatments.

  • Revenue in USD (TTM)0.00
  • Net income in USD-12.70m
  • Incorporated2012
  • Employees36.00
  • Location
    Enlivex Therapeutics Ltd14 Einstein St.NESS-ZIONA 7403618IsraelISR
  • Phone+972 86623301
  • Fax+972 86312981
  • Websitehttps://www.enlivex.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.